This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovative Journey of Kai Yuan
Introduction
Kai Yuan is an emerging inventor based in Nanjing, China. He is currently associated with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Despite having no granted patents to his name, he is actively involved in innovative research aimed at developing new pharmaceutical solutions. His work focuses on addressing critical health issues, particularly in the field of oncology.
Latest Patent Applications
Kai Yuan's notable patent application is titled "CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF." This invention discloses a compound represented by a specific general formula or a pharmaceutically acceptable salt thereof. The application outlines a preparation method for the compound and its potential use in preventing and treating various cancer-related diseases. These include breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, and human glioma. The compound is anticipated to be developed into a new generation of anticancer drugs.
Conclusion
Kai Yuan is a promising inventor whose work in pharmaceutical innovation holds significant potential for advancing cancer treatment. His dedication to research and development is evident in his latest patent application, which aims to contribute to the fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile